+

WO1995009005B1 - Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m - Google Patents

Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m

Info

Publication number
WO1995009005B1
WO1995009005B1 PCT/US1994/010923 US9410923W WO9509005B1 WO 1995009005 B1 WO1995009005 B1 WO 1995009005B1 US 9410923 W US9410923 W US 9410923W WO 9509005 B1 WO9509005 B1 WO 9509005B1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
oncostatin
interleukin
methods
cytokine
Prior art date
Application number
PCT/US1994/010923
Other languages
French (fr)
Other versions
WO1995009005A1 (en
Filing date
Publication date
Priority claimed from US08/312,205 external-priority patent/US5814307A/en
Application filed filed Critical
Priority to AU78447/94A priority Critical patent/AU7844794A/en
Priority to EP94929361A priority patent/EP0721344A1/en
Priority to JP7510413A priority patent/JPH09505560A/en
Publication of WO1995009005A1 publication Critical patent/WO1995009005A1/en
Publication of WO1995009005B1 publication Critical patent/WO1995009005B1/en

Links

Abstract

The present invention relates to methods of using oncostatin M (OM). In particular, it relates to the use of OM to stimulate interleukin 6 (IL-6) synthesis in target cells, especially human endothelial cells. The resultant IL-6, in turn, may perform a variety of functions such as cell growth regulation, leukocyte differentiation, and tumor inhibition. Furthermore, the present invention also relates to the use of OM to treat cytopenias, including anemia and thrombocytopoiesis, and to increase tolerance to irradiation and cytotoxic drugs. Therefore, the methods of the invention may have a wide range of applications, including, but not limited to, the inhibition of tumor growth, the treatment of cytopenias, and to increase the tolerance to radio- and chemotherapy. OM may be used in combination with various cytokines, including erythropoietin, colony-stimulating factors, interleukin-3 or thrombopoietin.

Claims

AMENDED CLAIMS [received by the International Bureau on 6 April 1995 (06.04.95) ; original claims 1 -24 replaced by new claims 1 -11 ( 1 page) ]
1. A composition comprising an effective amount of Oncostatin M for use in an individual to increase the number of blood cells to treat cytopenia.
2. The composition of claim 1, wherein the cytopenia is caused by transplantation of
hematopoeitic stem cells.
3. The composition, of claim 2, wherein the stem cells are from bone marrow.
4. The composition of claim 2, wherein the stem cells are from peripheral blood.
5. The composition of claim 1, wherein the cytopenia is caused by radiation or a cytotoxic drug.
6. The composition of claim 1, wherein the cytopenia is anemia or thrombocytopenia.
7. The composition of claim 1 , wherein Oncostatin M is combined by a cytokine.
8. The composition of claim 7, wherein the cytokine is erytbropoieten, granulocytc colony- stimulating factor, interleukin 3 and thrombopoieten.
9. A composition for use in increasing the maximum tolerated dose of radiation or cytotoxic drug comprising Oncostatin M.
10. The composition of claim 9, wherein Oncostatin M is combined with a cytokine.
11. The composition of claim 10, wherein the cytokine is erythropoieten, granulocyie colony- stimulating factor, interleukin 3 or thrombopoieten.
PCT/US1994/010923 1993-09-29 1994-09-27 Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m WO1995009005A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU78447/94A AU7844794A (en) 1993-09-29 1994-09-27 Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
EP94929361A EP0721344A1 (en) 1993-09-29 1994-09-27 Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
JP7510413A JPH09505560A (en) 1993-09-29 1994-09-27 Method for stimulating interleukin-6 synthesis using oncostatin M and method for inducing platelet production

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12923093A 1993-09-29 1993-09-29
US08/312,205 1994-09-26
US08/312,205 US5814307A (en) 1989-04-10 1994-09-26 Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US129,230 1994-09-26

Publications (2)

Publication Number Publication Date
WO1995009005A1 WO1995009005A1 (en) 1995-04-06
WO1995009005B1 true WO1995009005B1 (en) 1995-05-04

Family

ID=26827388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010923 WO1995009005A1 (en) 1993-09-29 1994-09-27 Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m

Country Status (6)

Country Link
US (1) US5814307A (en)
EP (1) EP0721344A1 (en)
JP (1) JPH09505560A (en)
AU (1) AU7844794A (en)
CA (1) CA2172808A1 (en)
WO (1) WO1995009005A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055319A1 (en) * 1999-03-12 2000-09-21 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
CZ298790B6 (en) * 1994-10-21 2008-01-30 Kishimoto@Tadamitsu Pharmaceutical composition for prevention or treatment of cachexia
CA2178256A1 (en) * 1995-06-06 1996-12-07 Christopher H. Clegg Oncostatin m induced hematopoiesis
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
WO2001049715A2 (en) * 2000-01-06 2001-07-12 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2000053751A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
PT1121439E (en) * 1998-10-13 2006-12-29 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
EP1135491A2 (en) * 1998-12-01 2001-09-26 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
CA2450402A1 (en) * 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
ATE353339T1 (en) * 1998-12-22 2007-02-15 Genentech Inc METHOD AND COMPOSITION FOR INHIBITING NEOPLASTIC CELL GROWTH
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU3246100A (en) * 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
AU2215300A (en) * 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
DK1185648T3 (en) * 1999-06-02 2007-07-30 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
IL160960A0 (en) * 2001-09-24 2004-08-31 Tosk Inc Reduced toxicity cisplatin formulations and methods for using the same
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
WO2007149328A1 (en) * 2006-06-20 2007-12-27 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
IL112767A (en) * 1989-04-10 1998-01-04 Oncogen Pharmaceutical compositions containing oncostatin m
US5202116A (en) * 1989-04-10 1993-04-13 Oncogen Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
US5744442A (en) * 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11

Similar Documents

Publication Publication Date Title
WO1995009005B1 (en) Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
Niitsu et al. Expression of TGF-beta gene in adult T cell leukemia
Uckun et al. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice
JP2004525957A5 (en)
Ogawa Effects of hemopoietic growth factors on stem cells in vitro
ATE71662T1 (en) PHARMACEUTICAL PREPARATION CONTAINING A HUMAN GRANULOCYTE COLONIZATION FACTOR FOR THE TREATMENT OF LEUKOPAENIA.
Baatout Interleukin-6 and megakaryocytopoiesis: an update
DE3771509D1 (en) PHARMACEUTICAL SUBSTANCE FOR PROMOTING THE RESTORATION OF HAEMATOPOIETIC CAPABILITY.
Hamblin Lymphokines and interleukins
EP0325471A1 (en) Method for suppressing the growth of normal and cancer cells
Crown et al. Interleukin-1: biological effects in human hematopoiesis
ES2036530T3 (en) USE OF A STIMULATING FACTOR OF HUMAN GRANULOCYTIC COLONIES TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYELOGENOUS LEUKEMIA.
Slørdal et al. Radioprotection by murine and human tumor‐necrosis factor: Dose‐dependent effects on hematopoiesis in the mouse
Ishizuka et al. Low molecular weight immunomodulators produced by microorganisms
Maury Anaemia in rheumatoid arthritis: role of cytokines
Obradovich et al. Effect of Recombinant Canine Granulocyte Colony‐stimulating Factor on Peripheral Blood Neutrophil Counts in Normal Cats
Ogilvie Hematopoietic growth factors: frontiers for cure
Veldhuis et al. Potential use of recombinant human interleukin-6 in clinical oncology
RU2647833C1 (en) Hemostimulating agent
Misawa et al. Effects of macrophage colony-stimulating factor and interleukin-2 administration on NK1. 1+ cells in mice
KAWATSU et al. Effect of conagenin on thrombocytopenia induced by antitumor agents in mice
Tefferi et al. Current perspective in agnogenic myeloid metaplasia
Smith Use of hematopoietic growth factors for treatment of aplastic anemia
Haan et al. Microenvironmentally dependent effects on murine haemopoiesis by a prolonged interleukin‐1 treatment
Hauke et al. Hematopoietic growth factors
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载